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Recognition of various HIV proteins by CD8 T cells from HIV-infected children was determined by two functional assays. First, using an
Elispot assay, we show that 80% of patients recognized Gag, 77% recognized Pol, 61% recognized Env, 44% recognized Nef and 29% recognized
Vif. Frequencies of Gag-, Pol-, and Env-specific IFN-γ producing CD8 T cells were higher than frequencies of Nef and Vif-specific CD8 T cells.
The poor recognition of Nef by ex vivo CD8 T cells was confirmed by CTL assays performed in HAART naïve children: 25% of children had
positive response against Nef versus 44, 63 and 62% for Env, Gag, and Pol, respectively. Memory Gag-specific CTL were positively correlated
with age, whereas Nef-specific CTL were negatively correlated with age. The poor Nef-specific CD8 T cell response in HIV-infected children
contrasts with dominance of Nef-specific responses in infected adults.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV; HIV perinatal infection; Elispot; CTL; CD8 T cell; ChildrenIntroduction
HIV-specific CD8 T cells play a major role by suppressing
HIV replication. However, characteristics and/or subsets of the
HIV-specific CD8 T cell response that correlate with their in
vivo antiviral potency are not completely defined. The diversity
and specificity of HIV-specific CD8 cells may be important for
the efficiency of this immune response. The diversity of the
CD8 T cell response may help to control virus bearing immune
escape mutations. The specificity is another important determi-
nant of CD8 T cell’s antiviral activity. As an example, earlier
epitope expression increases the antiviral efficiency of CD8 T
cells, probably through faster killing of productively infected
cells (Yang et al., 2003b). Recent reports on immune⁎ Corresponding author. Fax: +33 1 40 61 32 98.
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doi:10.1016/j.virol.2006.07.014recognition of the whole HIV genome highlight modification
of the CD8 T cell repertoire during the course of HIV infection
(Goulder et al., 2001; Alter et al., 2004). In particular, the HIV-
specific CD8 repertoires from patients in acute and chronic
phase of infection differ. Evolution of the CD8 repertoire is
probably driven by continuous stimulation, as early antiretro-
viral treatment that suppresses viral replication allows persis-
tence of early CD8 responses (Alter et al., 2003; Lichterfeld et
al., 2004). Furthermore, in chronically infected untreated adults,
diversity of HIV proteins recognition by CD8 T lymphocytes
decreases faster in patients with high viral load (Kousignian et
al., 2003). If the HIV-specific CD8 T cell repertoire is driven, at
least in part, by the level of viral replication, one might expect
differences between the CD8 repertoire of children and adults,
as children have higher level of viral replication than adults
(Mofenson et al., 1997; Rouzioux et al., 1997; Shearer et al.,
1997; Palumbo et al., 1998).
Fig. 1. The majority of HIV-specific IFN-γ producing cells from infected
children recognize the structural proteins of the virus. Blood samples obtained
from 51 HIV-1-infected children were tested for their IFN-γ production in
response to rVV encoding HIV-1Lai Env, Gag, Pol, Nef, Vif, Tat, or Rev. For
each HIV protein, percentages of positive and negative assays are presented in
panel A. For positive assays, frequencies of antigen-specific IFN-γ producing
cells, expressed as net SFC/106 PBMC, are presented in panel B. Black bars
represent mean values.
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We first defined recognition of seven viral proteins by HIV-
specific CD8 T cells from infected children using the highly
sensitive ex vivo IFN-γ-based Elispot assay. This study
revealed poor recognition of the nonstructural HIV-1 proteins.
In particular, rate of children with positive Nef-specific
responses was lower than rates of children responding to
structural proteins Env, Gag, and Pol. The low response to Nef
protein contrasts with other reports on the CD8 response from
adults (Betts et al., 2001; Addo et al., 2003; Bansal et al., 2003;
Cao et al., 2003; Currier et al., 2003; Draenert et al., 2004;
Masemola et al., 2004). At time of assessment of CD8 response
using the ex vivo Elispot assay, a significant fraction of children
were receiving or previously received potent antiretroviral
(ARV) therapy that alters HIV-specific CD8 T lymphocytes
frequency. Therefore, we performed a retrospective analysis of
memory cytotoxic T lymphocytes (CTL) from children that
never received potent ARV combination therapy. This second
study confirmed the poor recognition of Nef by CD8 T cells
from infected children and showed that the HIV-specific CD8 T
cell specificity varied according to age, with decreased Nef-
specific CTL and increased Gag-specific CTL in the oldest
children.
Results
Most HIV-specific CD8 T cells detected with an IFN-γ-based ex
vivo Elispot assay recognize HIV structural proteins
Recognition of HIV proteins by CD8 T cells from infected
children was systematically tested on blood samples from 51
HIV-1-infected children. Their freshly isolated PBMC were
incubated with rVVencoding HIV-1Lai Env, Gag, Pol, Nef, Vif,
Tat, or Rev, and IFN-γ production was measured by Elispot
assay, as described (Buseyne et al., 2005a). The most frequently
recognized proteins were Gag (80% of children had positive
responses), Pol (77%), and Env (61%) (Fig. 1A). Among
nonstructural proteins, Nef and Vif were recognized by 44 and
29% of children tested, respectively. None recognized either Tat
or Rev. In patients with positive responses, the frequencies of
IFN-γ producing cells varied according to the HIV protein
recognized, with mean values ranging from 822±822 SFC/106
PBMC for Gag to 97±51 SFC/106 PBMC for Vif (Fig. 1B).
Frequencies of IFN-γ producing cells were significantly
different when positive responses against five HIV antigens
were compared (ANOVA, p<0.0001). The Bonferroni/Dunn
test indicated significant differences between the frequencies of
IFN-γ producing cells in response to Nef and Gag (p<0.0001),
Nef and Env (p=0.004), Nef and Pol (p=0.003), Vif and Gag
(p=0.0009), and Vif and Pol (p=0.003). A significant number
of patients was of non-European origin and infected by
nonclade B HIV-1 isolates (see Patients and methods). We
may have underestimated the CD8 response of these patients, as
we used HIV-1 antigens derived from a clade B isolate.
Therefore, the analysis was restricted to the 36 patients with
documented HIV-1 clade B infection. Percent of patients with
positive responses were 73, 83, 88, 57 and 33% and mean ofpositive responses were 526±543, 827±739, 739±665, 178±
178 and 83±40 SFC/106 PBMC for Env, Gag, Pol, Nef and Vif
respectively (ANOVA, p<0.004). Thus, the hierarchy of HIV-1
protein recognition was similar for HIV-1 clade B-infected
children and the whole group, with slightly higher percentages
of positive responses for the former. In conclusion, HIV-specific
IFN-γ producing cells from infected children targeted structural
HIV-1 proteins (Env, Gag, and Pol) more frequently than the
four nonstructural proteins tested (Nef, Vif, Tat, and Rev). In
addition, responder patients have higher frequencies of IFN-γ
producing cells specific for structural proteins than for
nonstructural proteins.
Potent ARV therapy significantly affects the frequency of
HIV-specific CD8 T cell responses. Neither the rate of children
with positive responses nor the frequencies of specific IFN-γ
producing cells differed according to treatment status (p>0.05
for all χ2 and ANOVA tests). Of note, only 8 out of the 28
children treated with 3 or 4 ARVmolecules had suppressed viral
replication at time of assay. Using the same Elispot assay and a
rVV encoding Env, Gag, and Pol antigens simultaneously, we
recently reported that frequency of HIV-specific IFN-γ
producing cells was strongly associated with age in untreated
children, and was associated with both age and viremia in
children receiving potent combination ARV (Buseyne et al.,
2005b). Here, we observed a significant positive correlation
between the frequency of Gag-specific CD8 T cells and age
when both the whole group and untreated children were
273F. Buseyne et al. / Virology 354 (2006) 271–279analyzed (Pearson’s r=0.551, p=0.0002, n=39; untreated
children: Pearson’s r=0.557, p=0.03, n=15). The frequency
of CD8 T cells with other specificities was not related to age
(data not shown).
Differences in the rate of recognition of HIV proteins by CD8 T
cells are not due to use of recombinant Vaccinia viruses
We observed low-level recognition of the Nef protein
compared to other publications (Addo et al., 2003; Bansal et
al., 2003; Cao et al., 2003; Draenert et al., 2004; Masemola et
al., 2004). In these reports, pools of peptides were used to
induce IFN-γ production by PBMCs whereas we used rVV.Fig. 2. Differences in the rate of recognition of HIV proteins by CD8 T cells are not ex
PBMC from two children (left panels) and one adult (right panel) were tested for IFN-
using rVVor pools of overlapping peptides. (B) Freshly isolated PBMC from 13 HIV
the whole Gag and Nef sequence in the presence of brefeldin A. After 16 h, PBMCwe
by flow cytometry. Percent IFN-γ specific lymphocytes among total lymphocytes
uninfected or infected with wild-type Vaccinia, rVVencoding HIV-1 Gag protein (Va
cells were intracellularly labeled with antibodies specific for Vaccinia, HIV-1 Gag, o
serum. Fluorescence intensity is represented in histograms.Therefore, we compared peptide pools and rVV as source of
antigens in the ex vivo Elispot assay for two HIV-infected
children and one HIV-infected adult patient (Fig. 2A).
Frequencies of Gag and Nef IFN-γ producing cells were of
equivalent magnitude whether HIV proteins were encoded by
rVV or presented as pools of peptides. Furthermore, IFN-γ
production by PBMC from 13 HIV-infected children in the
presence of Gag and Nef peptide pools was measured by
intracellular cell cytometry (Fig. 2B). Frequencies of Gag-
specific CD8 cells were significantly higher than those of Nef-
specific CD8 cells (ANOVA, p=0.02). Ten out of the 13
children had positive response against Gag and 5 had positive
response against Nef. Among responder patients, percentsplained by the level of antigen expression by recombinant Vaccinia Viruses. (A)
γ production using the Elispot assay in response to HIV-1 Gag and Nef proteins,
-1-infected children were stimulated overnight with pools of peptides spanning
re stained with an anti-IFN-γ-PC7 monoclonal antibody and cells were analyzed
are presented. (C) Epstein-Barr transformed B lymphocytes were either left
cc-Gag), or rVVencoding HIV-1 Nef protein (Vacc-Nef). After 16 h of infection,
r HIV-1 Nef (as indicated above the panels) and a FITC-labeled anti-mouse IgG
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for Gag and 0.16±0.05 for Nef.
Protein expression by all rVV was measured by Western
blotting at time of vector construction, was regularly controlled
by immunolabeling, and these rVV allowed detection of HIV-
specific CTL of all specificities (Buseyne et al., 2002a;
Chouquet et al., 2002). Difference in the rate of recognition
of HIV proteins by infected patients could be related to the level
of antigen expression. In order to compare the expression of Nef
and Gag proteins in rVV-infected cells, Epstein-Barr trans-
formed B lymphocytes were infected by rVV and then labeled
with antibodies specific for Vaccinia antigens, HIV-1 Gag or
HIV-1 Nef. Intensity of Vaccinia protein expression was similar
for wild-type Vaccinia and both rVV (Fig. 2C, left panel). HIV-
Gag and HIV-Nef expression were detectable, with similar
fluorescence intensity, in Vacc-Gag and Vacc-Nef-infected
cells, respectively (Fig. 2C, right panels). Altogether, these
experiments exclude that low-level recognition of the HIV Nef
protein was due to low or absent antigen expression by rVV-
infected cells.
Recognition of HIV Env, Gag, Pol and Nef proteins by in vitro
stimulated CTL
We were interested in the low levels of responses against
regulatory proteins. In particular, the Nef-specific CD8 T cell
response from our group of HIV-infected children was
strikingly lower than the Nef-specific responses reported in
adult patients using ex vivo IFN-γ production assays (Addo et
al., 2003; Bansal et al., 2003; Cao et al., 2003; Draenert et al.,
2004; Masemola et al., 2004). The Elispot assays presented in
Fig. 1 were performed during the 1999–2001 period, when aFig. 3. Correlation between memory CTL and age in HAART naive children. Results
(AUC) and are presented as a function of age (expressed in years). Linear regression c
specific CTL; (D) Nef-specific CTL.significant proportion of children were receiving potent
combination that has profound impact on the CD8 T cell
responses in infected children (Spiegel et al., 2000; Scott et al.,
2001). We therefore decided to perform a retrospective analysis
of HIV-specific CD8 T cells children that never received
combination therapy including protease or nonnucleosidic
reverse transcriptase inhibitors (HAART naïve). At that time,
CD8 Tcells responses were measured by the 51Cr release assays
performed after in vitro expansion of PBMC, and recognition of
four HIV proteins (Env, Gag, Pol, and Nef) was systematically
tested on each blood sample (Buseyne et al., 1993, 1998a,
2002a).
Sixty-three patients that never received nNRTI or PI have
been tested for their cytolytic activity. The following analyses
were based on the assay performed at study entry. Percent of
children with positive responses were 44, 63, 62 and 25 for Env,
Gag, Pol and Nef, respectively. Magnitude of positive memory
CTL assays, expressed as AUC, was 826±416, 898±601, 983±
461 and 870±592 for Env, Gag, Pol, and Nef, respectively
(ANOVA p=0.66). For the forty-seven children with docu-
mented infection with HIV-1 subtype B, percent of children
with positive responses were 47, 70, 64 and 19% and mean
intensities of positive CTL assays, expressed as AUC, were
853±408, 891±605, 1008±475 and 906±533 for Env, Gag,
Pol, and Nef, respectively (ANOVA p=0.48). Thus, in absence
of potent combination therapy, CTL responses from HIV-
infected children targeted more frequently the three structural
proteins than the Nef protein.
During chronic viral infection, recognition pattern of
antigens by CD8 T cells evolved differently according to their
specificity (Goulder et al., 2001). We therefore investigated
whether age, which is approximately equal to the duration offrom CTL assays from 63-infected children are expressed as area under the curve
urves are shown. (A) Env-specific memory CTL; (B) Gag-specific CTL; (C) Pol-
Fig. 4. Frequency of HAART-naive children with positive memory CTL
response. The sixty-three children presented in Fig. 2 were stratified into four
age groups (0–2 years old, n=16; >2 and≤5 years old, n=9; >5 and≤10 years
old, n=27; >10 years old, n=11). Plasma viral load from the four age groups
were (from the youngest to the oldest): 5.7±0.4, 4.5±0.4, 4.2±0.8 and 4.1±1.3
log(HIV-RNA per ml of plasma), and their CD4+% were: 34±13, 33±10;
22±10, and 27±10. Percent of positive responses against each of the four HIV
proteins are presented for each age group.
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magnitude of memory CTL. Intensities of Gag-specific memory
CTL were positively correlated with age (Pearson’s r=0.346,
p=0.006; Fig. 3B). In contrast, Nef-specific memory CTL
were negatively correlated with age (Pearson’s r=−0.296,
p=0.02, Fig. 3D). The correlation between age and Gag-
specific memory CTL was confirmed using the Spearman rank
test, but the correlation between age and Nef-specific memory
CTL was not. Intensities of Env- and Pol-specific memory CTL
were not correlated with age (Pearson’s r=−0.176, p=0.16 and
r=0.113, p=0.38 for Env- and Pol-specific memory CTL,
respectively, Figs. 3A and C).
Then, children were stratified according to their age at time
of CTL assay and rates of children with positive memory CTL
responses were calculated for each target protein (Fig. 4). In
children less than 2 years old, rates of patients with positive
memory CTL assays against Env, Pol and Nef were similar,
around 40%. Rate of responder patients against Gag was twice
lower (19%). Rates of positive memory CTL responses against
Env- or Pol followed a bell-shaped curve as age increased, with
rates of responders being higher in children from the median age
groups (2–5 years old for Env, and 5–10 years old for Pol), than
in young (less than 2 years) or old children (>10 years). Rate of
responders against Nef declined with age. In contrast, rate of
responders against Gag was much higher after 2 years of age
(over 70% in the 3 age groups) than for children below 2 years
of age (19%). Thus, the pattern of HIV antigens recognized by
CD8 T cells from HAART naive HIV-infected children varies
according to age and to the target protein.
Discussion
The first part of this study was designed to determine the
targets of the HIV-specific CD8 T cell with ex vivo effector
function in HIV-1-infected children. The highest rates of
children with positive responses were observed for Env, Gag,
and Pol proteins. Nef and Vif proteins were recognized bylower rates of children and no response against Tat or Rev was
observed. Furthermore, for positive responses, frequencies of
IFN-γ producing cells specific for the three structural proteins
were higher than those of cells specific for Nef and Vif. In
adult patients, the regulatory (Tat and Rev) and accessory
proteins (Vif, Vpu, Vpr) contribute modestly to the total
magnitude of the CD8 T cell response and/or were less
frequently targeted when compared to Env, Gag, Pol, and Nef
(Addo et al., 2003; Cao et al., 2003; Draenert et al., 2004;
Masemola et al., 2004). In HIV-infected children, weak
recognition of Vif, Tat, and Rev was reported as well (Feeney
et al., 2003; Sandberg et al., 2003). Thus, the weak
recognition of Vif, Tat, and Rev in the present report is in
line with previous reports on the HIV-specific CD8 response
from both infected children and adults.
One striking feature of our results was the low frequency of
children with detectable CD8 T cell responses against Nef, and
the low magnitude of these Nef-specific responses using the
Elispot assay. We provided evidence that low-level recognition
of Nef was not due to low-level expression of the protein by
the rVV. Reduced Nef recognition in HIV-infected children
could be due to the expression of functional Nef by rVV
leading to down-regulation of MHC-I molecule. However,
higher level of Gag-specific than Nef-specific cells was
observed when peptide pools spanning the whole protein
sequence were used. This result excludes that poor Nef
recognition is due to MHC-I down regulation induced by the
functional Nef protein encoded by rVV. Nevertheless, we
cannot formally exclude that the Nef-induced MHC-I down-
regulation in rVV-infected cells further dampen detection of
Nef-specific CD8 T cells.
There are potential limitations for interpreting our data. One
of these is sequence mismatching between HIV strains infecting
patients and the HIV strain used for CD8 detection. This caveat
is inherent to any CD8 T cell study and leads to underestimation
of either frequency of positive response or intensity of response.
We previously evaluated cross-recognition of clade B and
nonclade B HIV isolates by CTL lines from the same study
group, and found that cross-recognition was the predominant
pattern (Buseyne et al., 1998b). Level of cross-recognition were
higher for Nef (83%) than for Gag (67%) (Buseyne et al.,
1998b), in accordance with another report based on 250
individuals from 4 continents (Coplan et al., 2005). In the
present study, around 20% of patients harbor nonclade B virus,
reflecting their diverse geographic origin. When we limited the
analysis to patients with documented clade B infection,
percentage of patients with positive responses and magnitude
of responses varied modestly, and hierarchy of HIV proteins
recognition was unchanged. Therefore, it is unlikely that low
level of Nef-specific CD8 responses compared to Gag-specific
CD8 responses could be explained by the diversity of HIV-1
strains infecting the patients.
The poor Nef-specific response can be explained by its
shorter size compared to those of the three structural proteins
and its higher sequence variability when compared to Gag and
Pol. In our study, dividing the percentage of responding patients
to each protein by the protein length expressed in amino acids,
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0.16, 0.07 and 0.07 for Nef, Gag, Pol, and Env responses with
the Elispot assay and 0.12, 0.12. 0.06, and 0.05 with the 51Cr
release assay. So, when the size of the Nef protein is taken into
account, its recognition by CD8 T cells is similar or greater than
that of structural proteins. Nevertheless, the level of Nef
recognition by our studied patients was low relative to other
published results in adults, as discussed below.
In adult patients, magnitude of responses and frequencies of
responders against HIV proteins varied according to reports, but
the relative dominance of Env, Gag, Pol, and Nef was constantly
observed, with rate of patients responding to Nef ranging from
57 to 95% (Betts et al., 2001; Addo et al., 2003; Bansal et al.,
2003; Cao et al., 2003; Currier et al., 2003; Draenert et al., 2004;
Masemola et al., 2004). The reduced recognition of Nef by
perinatally infected patients was not observed by Feeney et al.
(2003), but a study from Sandberg and colleagues reported Nef-
positive responses in only 25% of children, whereas 50 to 70%
of them recognized Env, Gag, or Pol (Sandberg et al., 2003).
Another report showed that CD8 T cell from pediatric patients
respond less frequently to the Nef protein and their responses
were of lower magnitude when compared to adult patients
(Chandwani et al., 2004). This study used both peptides and
Vaccinia viruses, excluding biases linked to the source of
antigen in the in vitro assay. Parallel study of patients matched
for therapy history and duration of infection are required to
definitively prove a reduced CD8 T cell response to Nef during
perinatally acquired HIV infection, when compared to infection
during adulthood. But our observation and those of other
investigators (Sandberg et al., 2003; Chandwani et al., 2004),
both suggest that HIV infection as newborn or as adult are
associated with different repertoires of the CD8 T lymphocytes
during chronic infection.
The study of ex vivo IFN-γ producing cells by the Elispot
assays began in mid-1999. At that time more than half of tested
children received potent ARV therapy including at least a
protease inhibitor or a nonnucleosidic reverse transcriptase
inhibitor. Suppression of viral replication leads to reduced
antigenic stimulation of CD8 responses that usually decrease in
treated children (Luzuriaga et al., 2000; Spiegel et al., 2000;
Buseyne et al., 2002b, 2005b). Therefore, we performed a
retrospective analysis of memory CTL from HAART naive
children, whose CD8 responses and disease progression were
not affected by potent therapy. One major difference with the
Elispot assay was that the 51Cr release assay was performed
after in vitro culture on selected lymphocytes with proliferative
capacity. The proliferative activity of CD8 T cells is associated
with high perforin content and control of disease progression
(Migueles et al., 2002). As the specificity of the CTL response is
known to change during the course of HIV infection (Goulder et
al., 2001; Alter et al., 2004), we presented results from CTL
assays as a function of age, which is almost equal to the duration
of infection in children. This second set of data confirmed the
low recognition of Nef by HIV-infected children. In addition, it
showed that in absence of potent ARV therapy intensities of
memory CTL responses and rates of positive responses were
correlated with age. For the three structural proteins, childrenyounger than two responded less frequently than older children.
The difference between young and old children was especially
marked for Gag-specific CTL. In children older than 10 years,
which are mostly slow progressors, the Gag-specific response
was dominant. This result is in line with the stronger inverse
correlation between Gag-specific CTL and plasma viral load,
when compared to CTL of other specificities (Buseyne et al.,
2002a). In sharp contrast to CTL targeting structural proteins,
Nef-specific memory CTL were more frequently detected in
children before the age of two, than after. Age in vertically
infected children reflects the duration of infection, and our
results are consistent with earlier detection of Nef-specific CTL
when compared to Env, Gag, or Pol-specific CD8 T cells in
adults (Alter et al., 2002; Addo et al., 2003; Lichterfeld et al.,
2004). However, CTL decrease with disease progression has
been described in untreated adults (Chouquet et al., 2002), but
preferential loss of Nef-specific CTL has never been reported.
Low rates of Nef-specific responses were observed in oldest
children compared to CTL of other specificities. This suggests
that Nef-specific CTL disappear earlier than CTL specific for
structural proteins. A longitudinal study will be required to
formally demonstrate different kinetics of HIV-specific CTL
according to their specificity. As for each child, a single CTL
assay against Env-, Gag, Pol and Nef was performed on the
same blood sample, our data definitely show that the
recognition pattern of HIV proteins by CD8 T cells differs
according to age/duration of infection over two decades and in
absence of treatment.
Our results raise the question of mechanisms that could lead
to difference in the HIV-specific CTL repertoire across the age
groups. Appearance of epitope escape mutation is usually
followed by the decay of specific CTL (Evans et al., 1999;
Jamieson et al., 2003). In vitro, emergence CTL escape
mutations is more rapid and consistent in Nef than in Gag or
RT sequences (Yang et al., 2003a). So, CTL specific for
structural proteins may be detected over longer period than Nef-
specific CTL, due to a lower rate of escape mutation in the
former. Interestingly, it was shown that the frequency of
mutations within CTL epitopes correlates positively with the
viral set-point (Barouch et al., 2002), which is higher for
pediatric patients than for adults and may accelerate the loss of
CTL directed to nonstructural proteins in infected children
(Mofenson et al., 1997; Rouzioux et al., 1997; Shearer et al.,
1997; Palumbo et al., 1998). A more speculative explanation for
the difference in rate of CD8 responses to Nef and Gag
according to age, could be their different sensitivity to the
deleterious effect of antigen persistence and antigen level, as
shown for other proteins in murine viral infection (Probst et al.,
2003). Evolution of the CTL response could be linked to
changes in viral sequence affecting expression level and
function. In pediatric infection, age is approximately equal to
duration of infection and older children are more likely to be
non/slow progressors than younger ones. Accumulation of
mutations affecting Nef expression have been reported in
nonprogressing perinatally infected children (Geffin et al.,
2000; Casartelli et al., 2003a, 2003b) and could lead to loss of
specific CD8 T cells. Alternatively, reduced Nef-mediated
277F. Buseyne et al. / Virology 354 (2006) 271–279MHC-I down-regulation may enhance recognition of late
proteins, such as Gag (Casartelli et al., 2003b).
In conclusion, we characterized the pattern of recognition
of HIV proteins by CD8 T cells from infected children using
two functional assays and during two different study periods.
We show that the repertoires of HIV-specific CD8 T cells
differ across age groups. The results suggest that attrition of
Nef-specific CD8 T cells occurs faster in infected children
when compared to adults. Furthermore, generation of Gag-
specific CTL appeared to be delayed in the youngest children
compared to CTL with other specificities, although Gag-
specific responses are dominant after 2 years of age and




The patients were followed at Necker Hospital in Paris.
Legal guardians gave informed consent before inclusion of the
children in the longitudinal follow-up of their CD8 T cells
activities and the study was approved by local ethic committee.
The presented results are based on two sets of data. For the first
study, results from Elispot assays in response to HIV-1 antigens
were obtained from June 1999 to April 2001. Children included
in the longitudinal follow-up were tested providing there were
sufficient PBMC to perform the assay. Among the 51 children
tested, 28 were receiving potent ARV therapy at time of assay.
Characteristics of patients (mean±SD) were as follows: 9.1±
5.0 years for age, 3.6±1.4 log (HIV RNA/ml) for plasma viral
load, 30±11 for CD4 percentages. This study group comprises
33 boys and 18 girls. Geographic origins were European (32),
sub-Saharan African (9), and others (10). HIV-1 subtypes were
determined using heteroduplex mobility assay HMA, as
previously described (Buseyne et al., 1998b), or using
phylogenetic analyses performed by estimating the relation-
ships among pol sequences and reference sequences of HIV-1
genetic subtypes and circulating recombinant forms obtained
from the Los Alamos Database (http://hiv-web.lanl.gov) (Chaix
et al., 2003). The patients harbored subtype A (n=2), subtype B
(n=36), subtype D (n=1), subtype F (n=2), subtype G (n=1),
or subtype CRF02 (n=2) HIV-1 strains. HIV-1 subtype was not
documented for 7 children.
The second study analyzed CTL assays from 63 HAART-
naive children, most of them obtained before 1996. We selected
CTL assays performed at study entry and before any treatment
including nonnucleosidic reverse transcriptase or protease
inhibitors. Children with progression to CDC stage C or death
before 12 months of age were excluded, as they have poor CTL
responses (Buseyne et al., 1998a). Characteristics of patients
(mean±SD) were as follows: 6.0±4.1 years for age, 4.7±
1.0 log(HIV RNA/ml) for plasma viral load, 27±12 for CD4+
percentages. This study group comprises 29 boys and 34 girls.
Geographic origins were European (38), sub-Saharan African
(13), and others (12). The patients harbored subtype A (n=3),
subtype B (n=47), subtype D (n=5), subtype F (n=3), orsubtype G (n=1) HIV-1 strains. HIV-1 subtype was not
documented for 4 children.
Vaccinia viruses
Recombinant Vaccinia viruses (rVV) encoding individual
HIV genes from the HIV-1Lai strain were obtained from
Transgène, Strasbourg, France. vvTG1139, vvTG1144,
vvTG3167, vvTG1147, vvTG1160, vvTG3196 and vvTG4113
encode the Env, Gag, Pol, Nef, Vif, Tat, and Rev proteins,
respectively (Buseyne et al., 1998b; Chouquet et al., 2002). The
parental Copenhagen Vaccinia strain was used as a negative
control. Expression of Vaccinia and HIV-1 antigens was
evaluated on Epstein-Barr transformed B lymphocytes infected
for 16 h at a m.o.i. of 10. Cells were fixed with paraformalde-
hyde and labeled with an anti-Vaccinia-specific polyclonal
ascite, a monoclonal Gag-specific antibody (MAb1542, Biorad,
provided by Dr. B. Parekh), or a Nef-specific antibody
(MATG0020 (Sol-Foulon et al., 2002)), and stained with a
FITC-labeled anti-mouse IgG (Biosys). Cells were analyzed on
a FACScalibur (Becton-Dickinson).
Elispot assay
Elispot assays were performed as previously described with
freshly isolated PBMC (Buseyne et al., 2002b, 2005a). Results
presented were obtained at a cell input of 5×105 PBMC/well.
rVV encoding HIV proteins were used at a final concentration
of 2×108 pfu/ml. Pools of overlapping peptides (15 mers
overlapping by 11 amino acids), corresponding to clade B
consensus sequence were obtained from the NIH (#8117 for
Gag; #5189 for Nef) and used at a final concentration of 1–
2 μg/ml for each peptide. The number of spots forming cells
(SFC) was determined with computer-assisted image analysis
software (KS-Elispot, Zeiss, Munich, Germany). An assay was
considered positive if (1) a minimum of 10 spots/well was
reach in the presence of antigen, and (2) the spot number
obtained in the presence of antigen exceeded the mean plus
3 SD of the spot number obtained with control antigen, and
(3) the spot number obtained in the presence of antigen was at
least twice the spot number obtained with control antigen. Net
SFC was calculated as: (SFC obtained with antigen)− (SFC
obtained with control antigen). Results were expressed as
SFC/106 PBMC=106×[(SFC number per well)/(number of
cell per well)].
Intracellular cell cytometry
Freshly isolated PBMC were seeded in RPMI-10% SVF and
incubated overnight in the presence of medium, Gag or Nef
peptide pools (NIH #8117 for Gag; #5189 for Nef). Brefeldin A
was added during the whole incubation period (2 μg/ml, Sigma-
Aldrich, Saint-Quentin Fallavier, France). Cells were stained
with CD3-FITC (BD bioscience, Le-Pont-de-Claix, France),
CD8β-PC5 (Beckman-Coulter, Villepinte, France) and CD4-
ECD (Beckman-Coulter) for 30 min at +4 °C. After washing
cells were fixed and permeabilized using the Intraprep kit
278 F. Buseyne et al. / Virology 354 (2006) 271–279(Beckman-Coulter), and stained with an anti-IFN-γ-PC7
monoclonal antibody (BD Biosciences) for 30 min at +4 °C,
washed and fixed with paraformaldehyde 1%. Labeled cells
were analyzed on FC500 flow cytometer (Coulter Electronics
Inc., Hialeah, FL). Events accumulation was followed up until
to reach 250,000 living cells on the lymphocyte gate which was
set up using both forward and right angle scatters. To allow
comparison with data from the Elispot assay, results were
expressed as percent among lymphocytes. The %peptide-
specific IFN-γ+ lymphocytes were calculated as follows: [%
IFN-γ+ cells in the presence of peptides]− [% IFN-γ+ cells in
the presence of medium]. The cut-off value used to define
positive response against peptide pools was the mean+2 SD of
%IFN-γ+ in presence of medium for the study group, that is
0.08%.
CTL assays
Freshly isolated PBMC were stimulated with PHA and
expanded in the presence of IL-2 for 3 weeks, and their HIV-
specific cytolytic activities were tested with the conventional
4-h 51Cr release assays as previously described (Buseyne et al.,
1998a, 1998b). Target cells were autologous Epstein-Barr
transformed B lymphocytes infected with rVV encoding HIV
antigens. The CTL responses against HIV antigens were
considered positive if specific lysis exceeded the mean of
control target lysis by three SD and by 10% of specific lysis, at
least at the highest effector to target (E/T) ratio. Positive
responses without dose-effect were discarded. Net specific lysis
was defined as the specific lysis of target cells expressing HIV-1
antigen minus specific lysis of control target cells. Areas under
the curve of net specific lysis (AUC) were calculated as
previously described (Lubaki et al., 1999; Buseyne et al.,
2002a): (l60+ l20)× (60−20)/2+(l20+ l7)× (20−7)/2, where l60,
l20 and l7 are the net specific lysis at E/T ratios of 60:1, 20:1 and
7:1, respectively.
Statistics
Differences in intensities of positive CD8 responses between
antigens were evaluated using ANOVA. For both the Elispot
and CTL assay, analyzed values followed a normal distribution.
The F test of variance equality showed that variance of
responses to antigens was equivalent for results of positive CTL
assays expressed as AUC, allowing use of AUC for ANOVA.
When results from positive Elispot assays towards the HIV
antigens were expressed as SFC/106PBMC, variances were
significantly different. Thus, results from Elispot assays were
expressed as log(SFC/106PBMC) to obtain equal variance
between groups and to perform statistical comparisons using
ANOVA. Multiple comparisons were performed with the
Bonferonni–Dunn method. Associations between quantitative
variables were defined by Pearson’s correlations, and confirmed
using the nonparametric Spearman rank test. All p values were
two-tailed and the significance level was set at 0.05. The
analysis was performed with Statview software (SAS Institute,
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